Literature DB >> 26543097

Biomarkers: A Challenging Conundrum in Cardiovascular Disease.

Peter Libby1, Kevin King2.   

Abstract

The use of biomarkers has proven utility in cardiovascular medicine and holds great promise for future advances, but their application requires considerable rigor in thinking and methodology. Numerous confounding factors can cloud the clinical and investigative uses of biomarkers. Yet, the thoughtful and critical use of biomarkers can doubtless aid discovery of new pathogenic pathways, identify novel therapeutic targets, and provide a bridge between the laboratory and the clinic. Biomarkers can provide diagnostic and prognostic tools to the practitioner. The careful application of biomarkers can also help design and guide clinical trials required to establish the efficacy of novel interventions to improve patient outcomes. Point of care testing, technological advances, such as microfluidic and wearable devices, and the power of omics approaches all promise to elevate the potential contributions of biomarkers to discovery science, translation, clinical trials, and the practice of cardiovascular medicine.
© 2015 American Heart Association, Inc.

Entities:  

Keywords:  biological markers; clinical trial; laboratories; prognosis; risk assessment

Mesh:

Substances:

Year:  2015        PMID: 26543097     DOI: 10.1161/ATVBAHA.115.305233

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  5 in total

Review 1.  Neutrophil Extracellular Traps Participate in Cardiovascular Diseases: Recent Experimental and Clinical Insights.

Authors:  Yvonne Döring; Peter Libby; Oliver Soehnlein
Journal:  Circ Res       Date:  2020-04-23       Impact factor: 17.367

Review 2.  Temporal shifts in clinical presentation and underlying mechanisms of atherosclerotic disease.

Authors:  Gerard Pasterkamp; Hester M den Ruijter; Peter Libby
Journal:  Nat Rev Cardiol       Date:  2016-10-20       Impact factor: 32.419

3.  Associations Between Systolic Interarm Differences in Blood Pressure and Cardiovascular Disease Outcomes and Mortality: Individual Participant Data Meta-Analysis, Development and Validation of a Prognostic Algorithm: The INTERPRESS-IPD Collaboration.

Authors:  Christopher E Clark; Fiona C Warren; Kate Boddy; Sinead T J McDonagh; Sarah F Moore; John Goddard; Nigel Reed; Malcolm Turner; Maria Teresa Alzamora; Rafel Ramos Blanes; Shao-Yuan Chuang; Michael Criqui; Marie Dahl; Gunnar Engström; Raimund Erbel; Mark Espeland; Luigi Ferrucci; Maëlenn Guerchet; Andrew Hattersley; Carlos Lahoz; Robyn L McClelland; Mary M McDermott; Jackie Price; Henri E Stoffers; Ji-Guang Wang; Jan Westerink; James White; Lyne Cloutier; Rod S Taylor; Angela C Shore; Richard J McManus; Victor Aboyans; John L Campbell
Journal:  Hypertension       Date:  2020-12-21       Impact factor: 10.190

4.  Prognosis and Reclassification by YKL-40 in Stable Coronary Artery Disease.

Authors:  Jakob Schroder; Janus Christian Jakobsen; Per Winkel; Jørgen Hilden; Gorm Boje Jensen; Ahmad Sajadieh; Anders Larsson; Johan Ärnlöv; Marina Harutyunyan; Julia S Johansen; Erik Kjøller; Christian Gluud; Jens Kastrup
Journal:  J Am Heart Assoc       Date:  2020-03-02       Impact factor: 5.501

5.  Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis.

Authors:  David C Klonoff; Jordan C Messler; Guillermo E Umpierrez; Limin Peng; Robby Booth; Jennifer Crowe; Valerie Garrett; Raymie McFarland; Francisco J Pasquel
Journal:  Diabetes Care       Date:  2020-12-15       Impact factor: 17.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.